[1]杨庆伟,梁海鹏△,陈小鹏,等.华蟾素胶囊联合多西他赛、奥沙利铂、替吉奥方案治疗晚期胃癌临床研究[J].陕西医学杂志,2020,49(7):884-888.[doi:DOI:10.3969/j.issn.10007377.2020.07.032]
　YANG Qingwei,LIANG Haipeng,CHEN Xiaopeng,et al.Clinical observation of huachansu capsules combined with chemotherapy in the treatment of advanced gastric cancer[J].,2020,49(7):884-888.[doi:DOI:10.3969/j.issn.10007377.2020.07.032]
点击复制

华蟾素胶囊联合多西他赛、奥沙利铂、替吉奥方案治疗晚期胃癌临床研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年7期
页码:
884-888
栏目:
药物与临床
出版日期:
2020-07-05

文章信息/Info

Title:
Clinical observation of huachansu capsules combined with chemotherapy in the treatment of advanced gastric cancer
作者:
杨庆伟1; 梁海鹏2△; 陈小鹏1; 彭世龙1
1.甘肃省庆阳市人民医院肿瘤外科(庆阳 745000); 2.甘肃省庆阳市人民医院普通外科(庆阳 745000)
Author(s):
YANG Qingwei; LIANG Haipeng; CHEN Xiaopeng; et al.
Department of Oncology,Qingyang People's Hospital,Gansu Province(Qingyang 745000)
关键词:
华蟾素;  多西他赛;  奥沙利铂;  替吉奥胶囊;  晚期胃癌
Keywords:
Huachansu;  Docetaxel;  Oxaliplatin;  Tegafur; gimeracil and oteracil potassium capsules;  Advanced gastric cancer
分类号:
R735.2
DOI:
DOI:10.3969/j.issn.10007377.2020.07.032
文献标志码:
A
摘要:
目的:观察华蟾素胶囊联合(多西他赛、奥沙利铂、替吉奥)方案治疗晚期胃癌的临床效果。方法:选取晚期胃癌患者60例,按随机数表法分为对照组和观察组各30例。对照组接受(多西他赛、奥沙利铂、替吉奥)方案化疗,观察组接受华蟾素胶囊联合(多西他赛、奥沙利铂、替吉奥)方案治疗,对比观察两组近期疗效、癌性疼痛、不良反应、肿瘤标志物和细胞因子水平等变化。结果:治疗后,观察组明显降低了骨髓抑制、胃肠道、脱发等不良反应的发生率,与对照组比较有统计学意义(P<0.05)。治疗后观察组CEA、CA199肿瘤标志物水和炎症因子白细胞介素-4(IL-4)和肿瘤坏死因子-α(TNF-α)平明显降低,与对照组相比差异有统计学意义(P<0.05)。观察组疼痛总缓解率60.00%高于对照组43.33%,差异有统计学意义(P<0.05)。近期疗效观察组总有效率73.33%高于对照组60.00%,差异有统计学意义(P<0.05)。结论:华蟾素胶囊联合(多西他赛+奥沙利铂+替吉奥)方案治疗晚期胃癌,能够更好的降低肿瘤标志物的表达,减轻化疗不良反应,缓解癌性疼痛,提高了患者的生活质量和近期疗效。
Abstract:
Objective:To observe the clinical effect of the combination of huachansu capsules and chemotherapy regimen(docetaxel,oxaliplatin,and tegafur,gimeracil and oteracil potassium capsules)in the treatment of advanced gastric cancer.Methods:60 patients with advanced gastric cancer were selected and divided into control group and observation group according to the random number table,30 cases each.The control group received chemotherapy regimen above mentioned,while the observation group received huachansu capsules on the basisi of control group.The short-term curative effect,cancer pain,adverse reactions,tumor markers and cytokine levels were compared between the two groups.Results:After treatment,the incidence of adverse reactions such as myelosuppression,gastrointestinal reaction and alopecia was significantly reduced in the observation group,which was statistically significant compared with the control group(P<0.05).After treatment,the levels of CEA,CA199,IL-4 and TNF-α were significantly reduced in the observation group,with statistically significant differences compared with the control group(P<0.05).The total pain relief rate in the observation group was 60.00%,which was higher than that in the control group(43.33%),with statistically significant difference(P<0.05).The total effective rate of the observation group was 73.33%,which was higher than that of the control group(60.00%),the difference was statistically significant(P<0.05).Conclusion:The combination of huachansu capsules and chemotherapy regimen(docetaxel,oxaliplatin,and tegafur,gimeracil and oteracil potassium capsules)can better reduce the expression of tumor markers,reduce the adverse reactions of chemotherapy,relieve cancer pain,improve the quality of life and short-term efficacy of patients.

参考文献/References:

[1] Rawla P,Barsouk A.Epidemiology of gastric cancer:global trends,risk factors and prevention[J].Prz Gastroenterol,2019,14(1):26-38.
[2] Kazuhiro N,Yasuhide Y,Kenji I,et al.Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase Ⅲ study of S-1 plus oxaliplatin versus S-1 plus cisplatin[J].Gastric Cancer,2017,20(4):640-645.
[3] 凌智君.华蟾素胶囊联合化疗对晚期胃癌患者的影响[J].临床研究,2019,27(9):140-141.
[4] 姜可伟.规范全球第二大致死率疾病的诊断《胃癌诊断标准》解读[J].中国卫生标准管理,2010,4(1):26-28.
[5] 严广斌.NRS疼痛数字评价量表numerical rating scale[J].中华关节外科杂志,2014,8(3):410.
[6] 丁 婕,戴 旭,孟宪运,等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复,2015,22(9):1150-1152.
[7] 丁海斌,常柏玲.康莱特联合DCF化疗方案在胃癌患者中的临床应用效果评价[J].癌症进展,2017,15(10):1176-1178.
[8] 薛世航,黄 芳,何 瑛,等.替吉奥胶囊治疗老年晚期胃癌的近期疗效和安全性探究[J].现代实用医学,2016,28(2):195-196.
[9] 薛丽英,南景龙,蔡智慧,等.XELOX方案和SOX方案治疗进展期胃癌疗效观察[J].中华实用诊断与治疗杂志,2014,28(4):369-371.
[10] 贾萌萌,杨 晶,王秀娟,等.多西他赛药动学参数在减少晚期卵巢癌患者血液毒性预测中的应用[J].中国医院药学杂志,2018,38(11):1192-1195.
[11] 王元清,严建业,喻林华.蟾皮的化学成分与临床应用研究进展[J].时珍国医国药,2009,20(5):1213-1214.
[12] 于秀荣,陈钧泽,李慧杰,等.华蟾素抗肿瘤研究[J].中医学报,2019,34(6):1174-1178.
[13] 何孟奇,邵淑丽,冯 元,等.华蟾素对胃癌细胞MKN-45细胞周期的影响[J].中国细胞生物学学报,2019,41(4):674-680.
[14] 王薇钧,卢 峻,牛川森,等.电针对慢性炎性反应疼痛大鼠血清TNF-α、IL-1、IL-4含量的影响[J].针刺研究,2010,35(6):429-432.
[15] 桂星花,马朝阳,高 英,等.火针联合电针法治疗带状疱疹的临床观察及对其血清IL-4、TNF-α的影响[J].辽宁中医杂志,2019,46(11):2399-2404.
[16] 巴茜远,周诗旸,罗欣欣,等.华蟾素抗癌性疼痛的药理作用及作用机制的研究进展[J].中国疼痛医学杂志,2019,25(9):695-698.

更新日期/Last Update: 2020-07-28